Research ExplorerPublicationsThe role of HE4 for prediction of recurrence in epithelial o...

The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study

Standard

The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study. / Nassir, Mani; Guan, Jun; Luketina, Hrvoje; Siepmann, Timo; Rohr, Irena; Richter, Rolf; Castillo-Tong, Dan Cacsire; Zeillinger, Robert; Vergote, Ignace; Van Nieuwenhuysen, Els; Concin, Nicole; Marth, Christian; Hall, Christina; Mahner, Sven; Woelber, Linn; Sehouli, Jalid; Braicu, Elena Ioana.

In: TUMOR BIOL, Vol. 37, No. 3, 01.03.2016, p. 3009-16.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Nassir, M, Guan, J, Luketina, H, Siepmann, T, Rohr, I, Richter, R, Castillo-Tong, DC, Zeillinger, R, Vergote, I, Van Nieuwenhuysen, E, Concin, N, Marth, C, Hall, C, Mahner, S, Woelber, L, Sehouli, J & Braicu, EI 2016, 'The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study', TUMOR BIOL, vol. 37, no. 3, pp. 3009-16. https://doi.org/10.1007/s13277-015-4031-9

APA

Nassir, M., Guan, J., Luketina, H., Siepmann, T., Rohr, I., Richter, R., Castillo-Tong, D. C., Zeillinger, R., Vergote, I., Van Nieuwenhuysen, E., Concin, N., Marth, C., Hall, C., Mahner, S., Woelber, L., Sehouli, J., & Braicu, E. I. (2016). The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study. TUMOR BIOL, 37(3), 3009-16. https://doi.org/10.1007/s13277-015-4031-9

Vancouver

Nassir M, Guan J, Luketina H, Siepmann T, Rohr I, Richter R et al. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study. TUMOR BIOL. 2016 Mar 1;37(3):3009-16. https://doi.org/10.1007/s13277-015-4031-9

Bibtex

@article{2b814933e82a44919bb5b37c03e19188,
title = "The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study",
abstract = "Patients with epithelial ovarian cancer (EOC) are at high risk of tumor recurrence. Human epididymis protein 4 (HE4) has been shown to be overexpressed in EOC. The primary aim of our study was to evaluate the role of HE4 in predicting recurrence in EOC patients. Furthermore, we assessed the role of HE4 in predicting recurrence after second-line chemotherapy. We retrospectively analyzed data of 92 out of 275 primary EOC patients of the multicenter project {"}Ovarian Cancer: Diagnosis of a silent killer{"} (OVCAD). The concentrations of HE4 and CA125 were determined preoperatively and 6 months after the end of platinum-based first-line chemotherapy (FU) using ELISA and Luminex technique, respectively. The role of HE4 and CA125 for prediction of recurrence was determined using receiver operating characteristics (ROC) curves. Out of 92 patients included, 70 (76 %) were responders and 22 (23 %) non-responders in terms of response to platinum-based first-line chemotherapy. Median HE4 concentrations at follow-up (FU) differed between responders and non-responders (60.5 vs. 237.25 pM, p = 0.0001), respectively. The combined use of HE4 and CA125 at FU with cut-off values of 49.5 pM and 25 U/ml for HE4 and CA125, respectively, for predicting recurrence within 12 months after first-line chemotherapy performed better than HE4 or CA125 alone (area under the curve (AUC) 0.928, 95 % confidence intervals (CI) 0.838-1, p < 0.001). HE4 at FU could predict recurrence within 6 months after second-line chemotherapy (AUC 0.719, 95 % CI 0.553-0.885, p = 0.024). The combination of both elevated biomarkers revealed significantly worse estimated median progression-free survival (PFS; hazard ratio (HR) 8.14, 95 % CI 3.75-17.68, p < 0.001) and slightly worse PFS in those in whom only one biomarker was elevated (HR 1.46, 95 % CI 0.72-2.96, p = 0.292) compared to those patients in whom no biomarker was elevated. For the estimated median overall survival (OS), our analysis revealed similar results. HE4 in combination with CA125 performed better than CA125 and HE4 alone in predicting recurrence within 12 months after first-line chemotherapy.",
author = "Mani Nassir and Jun Guan and Hrvoje Luketina and Timo Siepmann and Irena Rohr and Rolf Richter and Castillo-Tong, {Dan Cacsire} and Robert Zeillinger and Ignace Vergote and {Van Nieuwenhuysen}, Els and Nicole Concin and Christian Marth and Christina Hall and Sven Mahner and Linn Woelber and Jalid Sehouli and Braicu, {Elena Ioana}",
year = "2016",
month = mar,
day = "1",
doi = "10.1007/s13277-015-4031-9",
language = "English",
volume = "37",
pages = "3009--16",
journal = "TUMOR BIOL",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "3",

}

RIS

TY - JOUR

T1 - The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study

AU - Nassir, Mani

AU - Guan, Jun

AU - Luketina, Hrvoje

AU - Siepmann, Timo

AU - Rohr, Irena

AU - Richter, Rolf

AU - Castillo-Tong, Dan Cacsire

AU - Zeillinger, Robert

AU - Vergote, Ignace

AU - Van Nieuwenhuysen, Els

AU - Concin, Nicole

AU - Marth, Christian

AU - Hall, Christina

AU - Mahner, Sven

AU - Woelber, Linn

AU - Sehouli, Jalid

AU - Braicu, Elena Ioana

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Patients with epithelial ovarian cancer (EOC) are at high risk of tumor recurrence. Human epididymis protein 4 (HE4) has been shown to be overexpressed in EOC. The primary aim of our study was to evaluate the role of HE4 in predicting recurrence in EOC patients. Furthermore, we assessed the role of HE4 in predicting recurrence after second-line chemotherapy. We retrospectively analyzed data of 92 out of 275 primary EOC patients of the multicenter project "Ovarian Cancer: Diagnosis of a silent killer" (OVCAD). The concentrations of HE4 and CA125 were determined preoperatively and 6 months after the end of platinum-based first-line chemotherapy (FU) using ELISA and Luminex technique, respectively. The role of HE4 and CA125 for prediction of recurrence was determined using receiver operating characteristics (ROC) curves. Out of 92 patients included, 70 (76 %) were responders and 22 (23 %) non-responders in terms of response to platinum-based first-line chemotherapy. Median HE4 concentrations at follow-up (FU) differed between responders and non-responders (60.5 vs. 237.25 pM, p = 0.0001), respectively. The combined use of HE4 and CA125 at FU with cut-off values of 49.5 pM and 25 U/ml for HE4 and CA125, respectively, for predicting recurrence within 12 months after first-line chemotherapy performed better than HE4 or CA125 alone (area under the curve (AUC) 0.928, 95 % confidence intervals (CI) 0.838-1, p < 0.001). HE4 at FU could predict recurrence within 6 months after second-line chemotherapy (AUC 0.719, 95 % CI 0.553-0.885, p = 0.024). The combination of both elevated biomarkers revealed significantly worse estimated median progression-free survival (PFS; hazard ratio (HR) 8.14, 95 % CI 3.75-17.68, p < 0.001) and slightly worse PFS in those in whom only one biomarker was elevated (HR 1.46, 95 % CI 0.72-2.96, p = 0.292) compared to those patients in whom no biomarker was elevated. For the estimated median overall survival (OS), our analysis revealed similar results. HE4 in combination with CA125 performed better than CA125 and HE4 alone in predicting recurrence within 12 months after first-line chemotherapy.

AB - Patients with epithelial ovarian cancer (EOC) are at high risk of tumor recurrence. Human epididymis protein 4 (HE4) has been shown to be overexpressed in EOC. The primary aim of our study was to evaluate the role of HE4 in predicting recurrence in EOC patients. Furthermore, we assessed the role of HE4 in predicting recurrence after second-line chemotherapy. We retrospectively analyzed data of 92 out of 275 primary EOC patients of the multicenter project "Ovarian Cancer: Diagnosis of a silent killer" (OVCAD). The concentrations of HE4 and CA125 were determined preoperatively and 6 months after the end of platinum-based first-line chemotherapy (FU) using ELISA and Luminex technique, respectively. The role of HE4 and CA125 for prediction of recurrence was determined using receiver operating characteristics (ROC) curves. Out of 92 patients included, 70 (76 %) were responders and 22 (23 %) non-responders in terms of response to platinum-based first-line chemotherapy. Median HE4 concentrations at follow-up (FU) differed between responders and non-responders (60.5 vs. 237.25 pM, p = 0.0001), respectively. The combined use of HE4 and CA125 at FU with cut-off values of 49.5 pM and 25 U/ml for HE4 and CA125, respectively, for predicting recurrence within 12 months after first-line chemotherapy performed better than HE4 or CA125 alone (area under the curve (AUC) 0.928, 95 % confidence intervals (CI) 0.838-1, p < 0.001). HE4 at FU could predict recurrence within 6 months after second-line chemotherapy (AUC 0.719, 95 % CI 0.553-0.885, p = 0.024). The combination of both elevated biomarkers revealed significantly worse estimated median progression-free survival (PFS; hazard ratio (HR) 8.14, 95 % CI 3.75-17.68, p < 0.001) and slightly worse PFS in those in whom only one biomarker was elevated (HR 1.46, 95 % CI 0.72-2.96, p = 0.292) compared to those patients in whom no biomarker was elevated. For the estimated median overall survival (OS), our analysis revealed similar results. HE4 in combination with CA125 performed better than CA125 and HE4 alone in predicting recurrence within 12 months after first-line chemotherapy.

U2 - 10.1007/s13277-015-4031-9

DO - 10.1007/s13277-015-4031-9

M3 - SCORING: Journal article

C2 - 26419591

VL - 37

SP - 3009

EP - 3016

JO - TUMOR BIOL

JF - TUMOR BIOL

SN - 1010-4283

IS - 3

ER -